Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPITAL PCI AF: Rivaroxaban and Ticagrelor in AF Patients After PCI
NCT03331484Phase 3Completed
- Sponsor
- University of Ottawa Heart Institute
- Start
- Nov 2018
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ticagrelor and rivaroxaban in Atrial fibrillation (AFib) and acute coronary syndrome (ACS), sponsored by University of Ottawa Heart Institute. Primary endpoint: Composite of TIMI Bleeds at 12 months. Started Nov 2018; status: completed.
02
Drugs
ticagrelorrivaroxaban
03
Conditions
Atrial fibrillation (AFib)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03331484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331484.